Fenofibrate
Fenofibrate is a fibrate, a cholesterol and triglyceride medicine taken by mouth. The US label read, for Antara capsules, lists two uses in adults, as an add-on to diet: lowering triglycerides in severe hypertriglyceridemia, and lowering raised LDL cholesterol in primary hyperlipidemia when the recommended LDL-lowering treatment cannot be used. The label also says fenofibrate did not reduce coronary heart disease illness and death in two large randomized trials of people with type 2 diabetes.
Also called Antara
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 8703; UNII U202363UOS. MeSH descriptor D011345 is Fenofibrate. RxClass lists the FDA chemical class Fibric Acids and the established pharmacologic class Peroxisome Proliferator-activated Receptor alpha Agonist; the record is filed under the class page Fibrates on that evidence. The label read is the Lupin Pharmaceuticals, Inc. label for Antara capsules, application NDA021695, effective 2025-10-01 in openFDA, the label the class page already uses. The plan row pointed at a generic label (ANDA200920); the Antara brand label replaces it. Fenofibrate tablets, delayed-release capsules and the choline fenofibrate products have other labels and labelled uses and were not read. This page records the label indications, the label's statement on coronary heart disease outcomes and the mechanism sentence only: no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The Antara label says the active moiety is fenofibric acid, which increases lipolysis and the elimination of triglyceride-rich particles from plasma.
Claims and evidence
Context Adults with severe hypertriglyceridemia or primary hyperlipidemia, as described in the US label of Antara fenofibrate capsules
- Recipient
- Adult
- Population
- Adults with severe hypertriglyceridemia, and adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible, as the indications section of the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adults with severe hypertriglyceridemia
- Adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible
- Excluded
- None stated
The US label of Antara (fenofibrate capsules, Lupin Pharmaceuticals, Inc., application NDA021695; the version dated 2025-10-01 in openFDA) lists two uses as adjunctive therapy to diet in adults: reducing triglyceride levels in severe hypertriglyceridemia, and reducing elevated LDL cholesterol in primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. The label also says fenofibrate did not reduce coronary heart disease morbidity and mortality in two large randomized controlled trials of patients with type 2 diabetes mellitus. It calls the medicine a PPAR alpha agonist.
Applies to Adult Adults with severe hypertriglyceridemia or primary hyperlipidemia, as described in the US label of Antara fenofibrate capsules
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Fenofibrate products differ in form and in labelled uses; only the Antara capsule label was read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read.
- Retrieved
- Source effective date
- 2025-10-01
- Source state
- Current
- Version fingerprint
ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read.
- Retrieved
- Source effective date
- 2025-10-01
- Source state
- Current
- Version fingerprint
ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- Label passage quoted in the research quote table (FEN-LB-04, FEN-LB-05, FEN-LB-06).
- Retrieved
- Source effective date
- 2025-10-01
- Source state
- Current
- Version fingerprint
ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].description[0]
- How it applies
- Label passage quoted in the research quote table (FEN-LB-07).
- Retrieved
- Source effective date
- 2025-10-01
- Source state
- Current
- Version fingerprint
ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists reducing triglycerides in adults with severe hypertriglyceridemia as an indication: High triglycerides
Applies to Adult Adults with severe hypertriglyceridemia or primary hyperlipidemia, as described in the US label of Antara fenofibrate capsules
The US label of Antara (fenofibrate capsules, Lupin Pharmaceuticals, Inc., application NDA021695; the version dated 2025-10-01 in openFDA) lists two uses as adjunctive therapy to diet in adults: reducing triglyceride levels in severe hypertriglyceridemia, and reducing elevated LDL cholesterol in primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. The label also says fenofibrate did not reduce coronary heart disease morbidity and mortality in two large randomized controlled trials of patients with type 2 diabetes mellitus. It calls the medicine a PPAR alpha agonist.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Fenofibrate products differ in form and in labelled uses; only the Antara capsule label was read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reducing elevated LDL-C in adults with primary hyperlipidemia, when recommended LDL-C lowering therapy cannot be used, as an indication: Dyslipidemia
Applies to Adult Adults with severe hypertriglyceridemia or primary hyperlipidemia, as described in the US label of Antara fenofibrate capsules
The US label of Antara (fenofibrate capsules, Lupin Pharmaceuticals, Inc., application NDA021695; the version dated 2025-10-01 in openFDA) lists two uses as adjunctive therapy to diet in adults: reducing triglyceride levels in severe hypertriglyceridemia, and reducing elevated LDL cholesterol in primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. The label also says fenofibrate did not reduce coronary heart disease morbidity and mortality in two large randomized controlled trials of patients with type 2 diabetes mellitus. It calls the medicine a PPAR alpha agonist.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Fenofibrate products differ in form and in labelled uses; only the Antara capsule label was read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:fenofibrate- Content hash
785a4fd9ad4dfee9413cc37105a5310476aa666164bfa9777fa03058d7d3c14f